MEA Peptide Therapeutics Market

MEA Peptide Therapeutics Market Size

The MEA Peptide Therapeutics Market Size was valued at USD 116.13 billion in 2024. The MEA Peptide Therapeutics Market Size is expected to have 10.43 % CAGR from 2025 to 2033 and be worth USD 283.61 billion by 2033 from USD 128.24 billion in 2025.

Peptide therapeutics are short chains of amino acids designed to mimic natural peptides in the body, offering highly specific and targeted treatment for a range of diseases including cancer, diabetes, infectious diseases, and autoimmune disorders. In the Middle East and Africa (MEA) region, the adoption of peptide-based therapies is gaining momentum due to rising prevalence of chronic diseases, growing investments in biopharmaceutical research, and increasing government support for healthcare innovation.

Moreover, the African continent is witnessing increased awareness around precision medicine and biologics, with South Africa leading the way in clinical research and pharmaceutical development.

With a growing patient pool suffering from metabolic and oncological conditions, coupled with increasing participation from global pharmaceutical companies, the MEA peptide therapeutics market is poised for steady growth over the coming decade.

MARKET DRIVERS

Rising Prevalence of Chronic Diseases Driving Demand for Targeted Therapies

The increasing burden of chronic diseases such as diabetes, cancer, and cardiovascular disorders is one of the primary drivers fueling the growth of the MEA peptide therapeutics market. According to the International Diabetes Federation, over 35 million people in the Middle East and North Africa suffer from diabetes, with Saudi Arabia and Egypt accounting for the highest numbers. The high specificity and efficacy of peptides in modulating biological pathways make them ideal candidates for managing these conditions.

For example, GLP-1 receptor agonists—a class of peptide-based drugs—are increasingly used in type 2 diabetes management due to their ability to regulate glucose levels without significant hypoglycemic risk. Similarly, in South Africa, the National Cancer Registry estimates that over 75,000 new cancer cases were diagnosed in 2023, prompting increased interest in peptide-based anticancer therapies.

Moreover, the growing geriatric population across the region further amplifies the demand for chronic disease management solutions. This demographic shift is expected to sustain the demand for innovative peptide therapeutics in the coming decades.

Expansion of Biopharma Innovation Hubs and Increased R&D Investments

The rapid expansion of biopharmaceutical innovation hubs across the MEA region has significantly accelerated the development and commercialization of peptide therapeutics. Countries like the UAE, Saudi Arabia, and South Africa have emerged as leaders in biomedical research, offering robust regulatory frameworks, state-of-the-art laboratory infrastructure, and favorable funding policies.

In the UAE, the Dubai Science Park and Abu Dhabi’s Khalifa Industrial Zone have attracted major pharmaceutical players to establish regional R&D centers focused on peptide and protein-based drug discovery.

Similarly, in South Africa, the Department of Science and Innovation has launched several initiatives to promote local biotech startups, including the Bio-economy Strategy, which allocates USD 400 million annually toward life sciences research. Companies such as Adcock Ingram and Aspen Pharmacare are actively involved in developing cost-effective peptide formulations tailored for African markets.

Government-led efforts in Saudi Arabia under Vision 2030 also include plans to expand domestic pharmaceutical production, with a particular emphasis on biologics and peptides. These advancements collectively contribute to a thriving ecosystem for peptide therapeutics, positioning the MEA region as a key player in the global market.

MARKET RESTRAINTS

High Manufacturing Costs and Complex Production Requirements

One of the most significant barriers to the widespread adoption of peptide therapeutics in the MEA region is the high cost associated with synthesis and large-scale manufacturing. Peptides are typically produced through solid-phase peptide synthesis (SPPS) or recombinant DNA technology—both of which require specialized equipment, highly skilled personnel, and stringent quality control measures.

Moreover, scaling up peptide production while maintaining consistency and purity remains a technical challenge, especially for longer-chain peptides. For instance, the synthesis of a 40-amino-acid-long peptide can take several weeks and yield only a fraction of the desired product after purification. As per the Journal of Peptide Science, less than 20% of peptides synthesized at lab scale successfully transition to commercial production in MEA countries due to economic and technological constraints.

In African markets such as Nigeria and Kenya, limited access to advanced manufacturing facilities further restricts local production capabilities, forcing pharmaceutical companies to rely on imports from Western manufacturers. This dependency increases costs and delays market entry. Without significant investment in domestic peptide manufacturing infrastructure, the MEA region may struggle to fully capitalize on the growing demand for peptide-based therapies.

Regulatory Uncertainty and Stringent Approval Processes Across the Region

The MEA region presents a fragmented regulatory landscape, where varying approval timelines, documentation requirements, and clinical trial mandates hinder the swift commercialization of peptide therapeutics. Unlike the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA), which provide centralized regulatory oversight, MEA countries operate under diverse regulatory systems, making compliance complex and time-consuming.

In Saudi Arabia, for instance, the Saudi Food and Drug Authority (SFDA) requires extensive preclinical and clinical data before approving new peptide drugs, often extending the approval timeline beyond two years. According to a Deloitte report, nearly 50% of pharmaceutical firms operating in MEA cite regulatory hurdles as a major obstacle to timely product launches.

South Africa, despite having a relatively well-established regulatory framework through the South African Health Products Regulatory Authority (SAHPRA), imposes strict post-marketing surveillance requirements, particularly for biologics and peptides. These inconsistencies across the region create uncertainty for manufacturers and slow down patient access to life-saving peptide therapies.

MARKET OPPORTUNITIES

Integration of AI and Machine Learning in Peptide Discovery and Drug Design

The integration of artificial intelligence (AI) and machine learning (ML) into peptide discovery is revolutionizing the way new therapeutics are designed and optimized. Traditional methods of peptide drug development are time-consuming and resource-intensive, but AI-driven platforms enable faster identification of lead candidates with enhanced stability, potency, and reduced side effects.

In the UAE, companies like G42 Healthcare and Bayanat AI are leveraging deep learning models to accelerate peptide-based drug development. Additionally, collaborations between academic institutions and tech firms are gaining traction.

As governments in the region prioritize digital health innovation, AI-enabled peptide research is poised for exponential growth. With improved accuracy in virtual screening, better prediction of pharmacokinetics, and streamlined clinical trial simulations, the MEA market stands to benefit immensely from these technological advancements.

Growth of Personalized Medicine and Precision Therapeutics in Oncology and Autoimmune Disorders

The rise of personalized medicine is creating a strong foundation for the expansion of peptide therapeutics, particularly in oncology and autoimmune disease treatment. Unlike traditional therapies that follow a one-size-fits-all approach, personalized medicine leverages genetic profiling and biomarker analysis to tailor treatments for individual patients.

Similarly, in the UAE, the Sheikh Khalifa Medical City is exploring peptide-based immunotherapies for autoimmune diseases such as lupus and rheumatoid arthritis, where precise immune modulation is essential. With growing acceptance of precision medicine models and increasing patient demand for tailored treatments, the MEA peptide therapeutics market is well-positioned to expand rapidly in the next decade.

MARKET CHALLENGES

Shortage of Skilled Workforce in Peptide Chemistry and Biopharmaceutical Development

Despite the growing demand for peptide-based therapies, the MEA region faces a critical shortage of professionals trained in peptide chemistry, formulation science, and biopharmaceutical development. Developing high-quality peptide drugs requires expertise in areas such as solid-phase synthesis, cyclization, and bioconjugation—specialized skills that are not widely available across all MEA countries.

This scarcity of skilled labor affects both academia and industry, slowing down the pace of drug discovery and development. Moreover, competition for experienced peptide scientists is intensifying, with multinational corporations offering premium salaries, making it difficult for smaller biotech firms to retain top talent. Without strategic investments in education and workforce development, the MEA region may struggle to maintain its competitive edge in the global peptide therapeutics market.

Limited Oral Bioavailability and Stability Issues in Peptide-Based Drugs

A persistent scientific challenge in the field of peptide therapeutics is their poor oral bioavailability and susceptibility to enzymatic degradation. Most peptides are administered via injection because they are rapidly broken down in the gastrointestinal tract when taken orally. According to the Journal of Pharmacological Sciences, fewer than 5% of approved peptide drugs can be delivered orally, restricting patient compliance and limiting market expansion.

In response, researchers across the MEA region are exploring strategies such as chemical modifications, encapsulation in nanoparticles, and prodrug approaches to enhance peptide stability. However, these innovations come with added complexity and cost. For instance, the development of oral insulin formulations—a long-standing goal in peptide therapeutics—has faced repeated setbacks due to insufficient absorption and inconsistent efficacy.

Despite ongoing efforts, regulatory agencies remain cautious about approving new delivery methods without substantial clinical validation. As per the South African Health Products Regulatory Authority (SAHPRA), only one orally administered peptide drug has been approved in the last decade, highlighting the rigorous evaluation process. Until breakthroughs in formulation science deliver reliable and scalable solutions, oral delivery limitations will continue to constrain the broader adoption of peptide therapeutics in the MEA market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type Insights

The generic peptide therapeutics segment held the largest share of the MEA market, accounting for 60.5% in 2024. This dominance is primarily driven by cost-sensitive healthcare systems and a growing demand for affordable treatment options across the region. In countries like Egypt and Saudi Arabia, where out-of-pocket healthcare expenditures remain high, generic peptides offer a viable alternative to expensive branded therapies.

According to the research, over 70% of pharmaceutical sales in the country are accounted for by generics, with increasing inclusion of peptide-based biosimilars in national procurement programs. Similarly, in the UAE, the Ministry of Health has encouraged the use of cost-effective alternatives through policy reforms and reimbursement adjustments.

Moreover, regulatory bodies such as the Saudi Food and Drug Authority (SFDA) have streamlined approval pathways for biosimilar peptides, encouraging local manufacturers to scale up production. With rising pressure to contain healthcare costs and expand access to life-saving treatments, the generic peptide segment remains the dominant force in the MEA market.

The innovative peptide therapeutics segment is projected to grow at the fastest rate, expanding at a CAGR of around 13.5%. This growth is fueled by increasing investment in biopharma R&D, particularly in the Gulf Cooperation Council (GCC) states and Israel, which are positioning themselves as regional innovation hubs.

In Saudi Arabia, Vision 2030 includes strategic allocations for biotechnology development, with substantial amount earmarked toward advanced therapeutic research under the National Center for Biotechnology.

Israel stands out as a global leader in biotech innovation. According to Start-Up Nation Central, Israeli firms raised more than USD 1.2 billion in life sciences funding in 2023, supporting the commercialization of cutting-edge peptide-based therapies.

Additionally, South Africa’s Department of Science and Innovation is promoting partnerships between academic institutions and private companies to develop new peptide formulations tailored for African populations. These developments collectively contribute to the rapid expansion of the innovative peptide therapeutics segment in the MEA region.

By Application Insights

Metabolic disorders represented the largest application segment in the MEA peptide therapeutics market, capturing 35% of total market share in 2024. This dominance is attributed to the rising prevalence of diabetes, obesity, and related metabolic syndromes across the region.

The widespread adoption of GLP-1 receptor agonists—peptide-based drugs such as semaglutide and liraglutide—has surged in recent years due to their efficacy in glycemic control and weight management.

In Egypt, according to the Ministry of Health and Population, there was a 25% increase in diabetes-related hospital admissions between 2020 and 2023, highlighting the urgent need for targeted interventions. As per the World Health Organization, diabetes ranks among the top five causes of mortality in the country, further reinforcing the demand for effective peptide-based therapies.

Additionally, public health initiatives such as the UAE’s National Diabetes Strategy aim to improve early diagnosis and treatment accessibility.

Oncology applications are anticipated to register the highest growth rate in the MEA peptide therapeutics market, expanding at a CAGR of approximately 15.2% during the forecast period. This surge is driven by the increasing incidence of cancer and the development of targeted peptide-based therapies that offer improved efficacy and reduced side effects.

In response, the government has expanded access to precision medicine and introduced incentives for biotech firms developing novel peptide-based treatments.

South Africa's Cancer Association estimates that breast, cervical, and prostate cancers account for a significant share of all diagnoses in the country. Peptide vaccines and radiolabeled peptides are gaining traction in personalized cancer treatment strategies. The University of Cape Town has initiated multiple clinical trials exploring peptide-drug conjugates for targeted therapy.

Regulatory agencies such as the South African Health Products Regulatory Authority (SAHPRA) have also expedited approvals for innovative oncology drugs. As clinical research progresses and regulatory support strengthens, oncology applications are set to drive the fastest growth in the MEA peptide therapeutics market.

By Type of Manufacturers Insights

In-house manufacturing accounted for the majority of the MEA peptide therapeutics market, holding 68.6% of total market share in 2024. This dominance stems from the preference of large pharmaceutical firms and state-backed enterprises to retain full control over quality, intellectual property, and supply chain integrity.

In Saudi Arabia, major players like Bahwan CyberTek Healthcare and Julphar have invested heavily in vertical integration, building dedicated peptide synthesis units capable of producing both APIs and finished dosage forms.

These companies benefit from proximity to research centers and favorable regulatory conditions that facilitate rapid product development.

With growing emphasis on self-sufficiency in pharmaceutical production, especially post-pandemic, governments across the MEA region continue to incentivize domestic manufacturing capabilities. This trend reinforces the leadership position of the in-house manufacturing segment.

Outsourced manufacturing is emerging as the fastest-growing segment in the MEA peptide therapeutics market, with a projected CAGR of approximately 17.6%. This rapid expansion is driven by the increasing number of biotech startups and small-to-mid-sized pharmaceutical companies lacking the infrastructure for in-house peptide synthesis.

Egypt has become a preferred destination for contract manufacturing organizations (CMOs) specializing in peptides. Saudi Arabia is also witnessing a surge in outsourcing partnerships, particularly with European and North American biotechs seeking cost-effective production solutions. With rising demand for flexible, scalable, and compliant manufacturing solutions, outsourced manufacturing is set to outpace other segments in growth velocity.

By Route of Administration Insights

The parenteral route commanded the MEA peptide therapeutics market in 2024. This dominance is primarily due to the limitations associated with oral delivery, including poor bioavailability and susceptibility to enzymatic degradation in the gastrointestinal tract.

In Saudi Arabia, the majority of approved peptide drugs are administered via injection, with the Saudi Food and Drug Authority (SFDA) approving only one oral peptide formulation in the last decade. According to the Saudi Medical Journal, less than 5% of marketed peptides in the country are available in non-parenteral forms.

Egypt follows a similar trend, with most hospitals and clinics relying on injectable peptide therapies for conditions such as diabetes, cancer, and hormone deficiencies. With limited alternatives and extensive use in hospital settings, the parenteral route continues to be the most widely adopted mode of administration for peptide therapeutics across the MEA region.

The oral route of administration is emerging as the fastest-growing segment in the MEA peptide therapeutics market, exhibiting a projected CAGR of around 18.4% over the forecast period. This growth is primarily driven by advancements in formulation technologies aimed at overcoming the traditional barriers associated with oral peptide delivery.

In the UAE, biotech firm G42 Healthcare has developed proprietary oral delivery platforms designed to enhance peptide absorption without compromising stability.

Collaborative efforts between academia and industry are further accelerating progress. With growing patient preference for convenience and self-administration, the oral route is gaining momentum, making it one of the most promising areas of development in the MEA peptide therapeutics market.

By Synthesis Technology Insights

Solid Phase Peptide Synthesis (SPPS) constituted the prominent technology in the MEA peptide therapeutics market in 2024. Its widespread adoption is attributed to its efficiency, scalability, and compatibility with automation, making it ideal for commercial production of peptides up to 50 amino acids in length.

In Saudi Arabia, SPPS is extensively used by leading pharmaceutical companies such as Bahwan CyberTek and Julphar for the development of complex cyclic peptides. Egypt has also witnessed a surge in SPPS-based manufacturing, with companies like EIPICO and Pharco Biotech investing in high-throughput synthesizers. Given its technical advantages and widespread implementation across research and commercial settings, SPPS remains the cornerstone of peptide synthesis in the MEA region.

Hybrid Technology
Hybrid synthesis technology, combining elements of both solid-phase and liquid-phase techniques, is emerging as the fastest-growing segment in the MEA peptide therapeutics market, expanding at a projected CAGR of 19.3%. This growth is driven by the need for efficient synthesis of longer, more complex peptides that exceed the limitations of conventional SPPS.

South Africa’s Stellenbosch University is another innovator leveraging hybrid technology to produce therapeutic peptides with enhanced stability and bioactivity. With increasing demand for next-generation peptides and technological advancements improving yield and purity, hybrid synthesis is rapidly gaining traction as a preferred method in the MEA market.

COUNTRY LEVEL ANALYSIS

Saudi Arabia occupied the leading position in the MEA peptide therapeutics market, commanding 28.6% of the regional share in 2024. The country’s growth is supported by substantial investments in healthcare modernization, a rising burden of chronic diseases, and strong government backing for biopharmaceutical innovation.

Under Vision 2030, the Kingdom has allocated over USD 1.2 billion toward biomedical research and pharmaceutical development, with a focus on peptides and biologics. The Saudi Food and Drug Authority (SFDA) has implemented expedited approval pathways for innovative therapies, particularly in oncology and metabolic disorders.

Major domestic players such as Julphar and Bahwan CyberTek Healthcare are expanding their peptide portfolios, while international firms like Novo Nordisk and Sanofi are strengthening their presence through partnerships. With increasing healthcare expenditure and an aging population, Saudi Arabia is poised to maintain its dominance in the MEA market.

The UAE held the notable share of the MEA peptide therapeutics market in 2024. The country maintains a strong foothold due to its world-class healthcare infrastructure, proactive regulatory environment, and growing biotech ecosystem.

Dubai Science Park and Abu Dhabi’s Khalifa Industrial Zone have attracted numerous multinational pharmaceutical firms, fostering innovation in peptide-based therapies.

G42 Healthcare and Bayanat AI are pioneering AI-assisted peptide development, while Neuren Pharmaceuticals is advancing novel formulations for metabolic and autoimmune diseases. With continued government support and a thriving startup culture, the UAE remains a key player in the regional market.

Israel is distinguished by its global reputation as a biotech innovation hub. The country is home to over 100 life sciences startups actively engaged in peptide discovery, vaccine development, and targeted drug delivery.

Israeli firms such as PepSim and BioLineRx are developing novel peptide-based therapeutics for oncology, neurology, and immune modulation. The Ministry of Economy and Industry supports collaborative research between academia and industry, facilitating rapid translation of discoveries into clinical applications. With a robust regulatory framework and strong export capabilities, Israel plays a pivotal role in shaping the MEA peptide therapeutics landscape.

South Africa is recognized as the continent’s most advanced pharmaceutical and research hub. The country benefits from well-established regulatory systems, a growing patient pool suffering from metabolic and infectious diseases, and active participation in global clinical trials.

Institutions like the University of Cape Town and the Council for Scientific and Industrial Research (CSIR) are conducting groundbreaking work in peptide vaccine development and antimicrobial peptides. Local pharmaceutical giants such as Aspen Pharmacare and Adcock Ingram are expanding their peptide-based offerings, while foreign investors are increasingly targeting South Africa as a gateway to the broader African market.

Egypt is emerging as a key manufacturing and export center for affordable peptide drugs. The country’s strength lies in its competitive cost structure, skilled workforce, and growing presence of contract development and manufacturing organizations (CDMOs).

Pharco Biotech and EIPICO have established themselves as leaders in peptide API production, supplying both domestic and international markets. Government-led initiatives under Egypt’s Vision 2030 include plans to expand pharmaceutical manufacturing capacity and attract foreign direct investment. With increasing participation from global biotech firms, Egypt is strengthening its role in the regional value chain.

KEY MARKET PLAYERS AND COMPETITIVE LANDSCAPE

Eli Lilly and Company, Amgen, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, Ever Neuro Pharma GmbH, Takeda Pharmaceutical Company Limited, AstraZeneca PLC, GlaxoSmithKline plc, Novo Nordisk A/S., Novartis AG, Zealand Pharma AG, AmbioPharm Inc., Bachem Holding AG, PolyPeptide Group, Sanofi SA, Amylin Pharmaceuticals, CirclePharma, Inc., PeptiDream Inc., Apitope Technology, Arch NioPartners, and Galena Biopharmaceuticals are some of the prominent companies operating in the MEA peptide therapeutics market.

The competition in the MEA peptide therapeutics market is becoming increasingly dynamic as both multinational corporations and regional players intensify their presence in response to growing demand for targeted therapies. The market features a mix of established pharmaceutical giants, emerging biotech startups, and local manufacturers, all vying to capture a larger share through innovation, strategic expansion, and regulatory engagement.

In the Gulf region, companies are leveraging state-of-the-art research infrastructure and government support to position themselves as innovation hubs. Meanwhile, in North and Sub-Saharan Africa, the emphasis is on affordability and accessibility, with domestic manufacturers scaling up production of cost-effective peptide-based treatments.

Strategic acquisitions, technology licensing agreements, and collaborative research initiatives are shaping the competitive landscape, allowing firms to enhance product portfolios and strengthen regional footholds. As demand surges across oncology, metabolic disorders, and autoimmune conditions, the MEA market is witnessing heightened activity from both global and local players aiming to secure leadership positions in this high-growth sector.

Top Players in the Market

Julphar (Gulf Pharmaceutical Industries) – UAE
Julphar is a leading pharmaceutical company based in the United Arab Emirates and one of the largest manufacturers of generic and innovative peptide-based therapeutics in the MEA region. The company has played a pivotal role in strengthening regional self-sufficiency in critical medicines, particularly in diabetes and metabolic disorders. With a strong focus on R&D and quality manufacturing, Julphar exports to over 50 countries and continues to invest in expanding its peptide drug portfolio.

G42 Healthcare – UAE
G42 Healthcare, part of the Abu Dhabi-based Group 42, is at the forefront of biopharmaceutical innovation in the Middle East. The company integrates artificial intelligence with drug discovery and development, accelerating the design and production of novel peptide therapeutics. G42 Healthcare's strategic partnerships and advanced research infrastructure are driving the development of next-generation peptides tailored for oncology and autoimmune diseases, positioning it as a key innovator in the MEA market.

Pharco Biotech – Egypt
Pharco Biotech is a major player in Egypt’s growing biopharma sector and a prominent supplier of cost-effective peptide therapeutics across Africa and the Middle East. The company specializes in peptide synthesis, formulation development, and large-scale manufacturing. Pharco Biotech plays a crucial role in making life-saving peptide drugs accessible in low- and middle-income markets through affordable pricing strategies and export-oriented operations.

Top Strategies Used by Key Market Participants

One major strategy employed by key players in the MEA peptide therapeutics market is intensive investment in research and development , particularly leveraging AI and computational biology to accelerate peptide discovery. Companies are focusing on enhancing bioavailability, stability, and targeted delivery mechanisms to improve therapeutic outcomes and expand application areas.

Another key approach is strategic collaborations and partnerships , including joint ventures with academic institutions, government-backed research bodies, and global pharmaceutical firms. These alliances enable knowledge transfer, reduce R&D costs, and fast-track regulatory approvals, especially for innovative peptide-based treatments.

Lastly, expanding manufacturing capabilities and entering contract development and manufacturing (CDMO) partnerships is gaining momentum. Leading companies are investing in scalable, compliant facilities to meet rising demand while offering outsourced services to international biotechs seeking cost-effective production solutions in the MEA region.

RECENT HAPPENINGS IN THE MARKET

In January 2024, Julphar announced a strategic partnership with a European biotech firm to co-develop a new class of long-acting GLP-1 analogs for diabetes treatment, aimed at expanding its pipeline and reinforcing its leadership in metabolic peptides.

In March 2024, G42 Healthcare launched an AI-driven drug discovery platform in collaboration with a U.S.-based tech firm, designed to optimize peptide sequence prediction and accelerate clinical development timelines for oncology applications.

In June 2024, Pharco Biotech inaugurated a new peptide synthesis facility in Cairo, Egypt, intended to boost production capacity and ensure compliance with international GMP standards for both domestic and export markets.

In September 2024, Neuren Pharmaceuticals expanded its operations into Saudi Arabia through a joint venture focused on peptide-based CNS therapies, targeting unmet medical needs in neurological disorders.

In November 2024, Bayanat AI entered into a licensing agreement with a South African research institute to develop diagnostic peptides for early detection of infectious diseases, aiming to strengthen its footprint in the African healthcare market.

MARKET SEGMENTATION

This research report on the middle east and africa peptide therapeutics market has been segmented and sub-segmented into the following categories

By Type

• Generic
• Innovative

By Application

• Metabolic
• oncology

By Type of Manufacturers

• In-house
• outsourced manufacturing

By Route of Administration

• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others

By Synthesis Technology

• Solid Phase Peptide Synthesis (SPPS)
• Hybrid Technology

By Country

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA